Evaluation of the Ocular Tolerance of Three Tacrolimus Topical Pharmaceutical Preparations by Bovine Corneal Opacity and Permeability Test

References

• Attas-Fox L, Barkana Y, Iskhakov V, Rayvich S, Gerber Y, Morad Y, et al. Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study. Curr Eye Res 2008;33:545–549.
   PubMed Web of Science ®Google Scholar
• Magalhaes OA, Marinho DR, Kwitko S. Topical 0.03% tacrolimus preventing rejection in high-risk corneal transplantation: a cohort study. Br J Ophthalmol 2013;97:1395–1398.
   PubMed Web of Science ®Google Scholar
• Kymionis GD, Goldman D, Ide T, Yoo SH. Tacrolimus ointment 0.03% in the eye for treatment of giant papillary conjunctivitis. Cornea 2008;27:228–229.
   Google Scholar
• Tam PM, Young AL, Cheng LL, Lam PT. Topical tacrolimus 0.03% monotherapy for vernal keratoconjunctivitis – case series. Br J Ophthalmol 2010;94:1405–1406.
   PubMed Web of Science ®Google Scholar
• Al-Amri AM. Long-term follow-up of tacrolimus ointment for treatment of atopic keratoconjunctivitis. Am J Ophthalmol 2014;157:280–286.
   PubMed Web of Science ®Google Scholar
• Virtanen HM, Reitamo S, Kari M, Kari O. Effect of 0.03% tacrolimus ointment on conjunctival cytology in patients with severe atopic blepharoconjunctivitis: a retrospective study. Acta Ophthalmol Scand 2006;84:693–695.
   PubMedGoogle Scholar
• Lee RW, Greenwood R, Taylor H, Amer R, Biester S, Heissigerova J, et al. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis. Ophthalmology 2012;119:1223–1230.
   PubMed Web of Science ®Google Scholar
• Letko E, Ahmed AR, Foster CS. Treatment of ocular cicatricial pemphigoid with tacrolimus (FK 506). Graefes Arch Clin Exp Ophthalmol 2001;239:441–444.
   PubMed Web of Science ®Google Scholar
• Armstrong VW, Oellerich M. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem 2001;34:9–16.
   PubMed Web of Science ®Google Scholar
• Barequet IS, Platner E, Sade K, Etkin S, Ziv H, Rosner M, et al. Topical tacrolimus for the management of acute allergic conjunctivitis in a mouse model. Graefes Arch Clin Exp Ophthalmol 2013;251:1717–1721.
   PubMed Web of Science ®Google Scholar
• Tam PM, Young AL, Cheng LL, Lam PT. Topical 0.03% tacrolimus ointment in the management of ocular surface inflammation in chronic GVHD. Bone Marrow Transplant 2010;45:957–958.
   PubMed Web of Science ®Google Scholar
• Davila-Fajardo CL, Cabeza Barrera J, Vallejo Rodriguez I, Garcia Serrano JL. Ophthalmic tacrolimus cream for the treatment of immunological corneal ulcers. Farm Hosp 2009;33:112–113.
   PubMedGoogle Scholar
• Busch JC, RA; Ibanez P, Swanson K. Final report on the safety assessment of propylene carbonate. J Am College Toxicol 1987;6:29.
   PubMedGoogle Scholar
• Reinhard T, Mayweg S, Reis A, Sundmacher R. Topical FK506 as immunoprophylaxis after allogeneic penetrating normal-risk keratoplasty: a randomized clinical pilot study. Transpl Int 2005;18:193–197.
   PubMed Web of Science ®Google Scholar
• Labcharoenwongs P, Jirapongsananuruk O, Visitsunthorn N, Kosrirukvongs P, Saengin P, Vichyanond P. A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. Asian Pac J Allergy Immunol 2012;30:177–184.
   PubMed Web of Science ®Google Scholar
• Cooper KJ, Earl LK, Harbell J, Raabe H. Prediction of ocular irritancy of prototype shampoo formulations by the isolated rabbit eye (IRE) test and bovine corneal opacity and permeability (BCOP) assay. Toxicol In Vitro 2001;15:95–103.
   PubMed Web of Science ®Google Scholar
• OECD. Test No. 437: Bovine corneal opacity and permeability test method for identifying i) chemicals inducing serious eye damage and ii) chemicals not requiring classification for eye irritation or serious eye damage. OECD Guidelines for the Testing of Chemicals; 2013. p. 27.
   Google Scholar
• Schrage A, Kolle SN, Moreno MC, Norman K, Raabe H, Curren R, et al. The bovine corneal opacity and permeability test in routine ocular irritation testing and its improvement within the limits of OECD test guideline 437. Altern Lab Anim 2011;39:37–53.
   PubMed Web of Science ®Google Scholar
• Chen W, Hu J, Zhang Z, Chen L, Xie H, Dong N, et al. Localization and expression of zonula occludins-1 in the rabbit corneal epithelium following exposure to benzalkonium chloride. PLoS One 2012;7:e40893.
   Google Scholar
• Zhu YT, Hayashida Y, Kheirkhah A, He H, Chen SY, Tseng SC. Characterization and comparison of intercellular adherent junctions expressed by human corneal endothelial cells in vivo and in vitro. Invest Ophthalmol Vis Sci 2008;49:3879–3886.
   PubMed Web of Science ®Google Scholar
• Sugrue SP, Zieske JD. ZO1 in corneal epithelium: association to the zonula occludens and adherens junctions. Exp Eye Res 1997;64:11–20.
   PubMed Web of Science ®Google Scholar
• Li L, Hartley R, Reiss B, Sun Y, Pu J, Wu D, et al. E-cadherin plays an essential role in collective directional migration of large epithelial sheets. Cell Mol Life Sci 2012;69:2779–2789.
   PubMed Web of Science ®Google Scholar
• Dholakiya SL, Barile FA. Alternative methods for ocular toxicology testing: validation, applications and troubleshooting. Expert Opin Drug Metab Toxicol 2013;9:699–712.
   PubMed Web of Science ®Google Scholar
• Kikuchi T, Suzuki M, Kusai A, Iseki K, Sasaki H. Synergistic effect of EDTA and boric acid on corneal penetration of CS-088. Int J Pharm 2005;290:83–89.
   PubMed Web of Science ®Google Scholar
• Chan WY, Cheung KK, Schorge JO, Huang LW, Welch WR, Bell DA, et al. Bcl-2 and p53 protein expression, apoptosis, and p53 mutation in human epithelial ovarian cancers. Am J Pathol 2000;156:409–417.
   PubMed Web of Science ®Google Scholar
• Milara J, Peiro T, Serrano A, Cortijo J. Epithelial to mesenchymal transition is increased in patients with COPD and induced by cigarette smoke. Thorax 2013;68:410–420.
   PubMed Web of Science ®Google Scholar
• Hussein MR. Analysis of Bcl-2 protein expression in choroidal melanomas. J Clin Pathol 2005;58:486–489.
   PubMed Web of Science ®Google Scholar
• Fukushima A, Ohashi Y, Ebihara N, Uchio E, Okamoto S, Kumagai N, et al. Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement. Br J Ophthalmol 2014;98:1023–1027.
   PubMed Web of Science ®Google Scholar
• Tzu JH, Utine CA, Stern ME, Akpek EK. Topical calcineurin inhibitors in the treatment of steroid-dependent atopic keratoconjunctivitis. Cornea 2012;31:649–654.
   PubMed Web of Science ®Google Scholar
• Baranowski P, Karolewicz B, Gajda M, Pluta J. Ophthalmic drug dosage forms: characterisation and research methods. ScientificWorldJournal 2014;2014:861904.
   PubMed Web of Science ®Google Scholar
• Hogan AC, McAvoy CE, Dick AD, Lee RW. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis. Ophthalmology 2007;114:1000–1006.
   PubMed Web of Science ®Google Scholar
• Wyrsch S, Thiel MA, Becht CN. [Safety of treatment with tacrolimus ointment for anterior segment inflammatory diseases]. Klin Monbl Augenheilkd 2009;226:234–236.
   PubMed Web of Science ®Google Scholar
• Ebihara N, Ohashi Y, Fujishima H, Fukushima A, Nakagawa Y, Namba K, et al. Blood level of tacrolimus in patients with severe allergic conjunctivitis treated by 0.1% tacrolimus ophthalmic suspension. Allergol Int 2012;61:275–282.
   PubMed Web of Science ®Google Scholar
• Contreras-Ruiz L, Schulze U, Garcia-Posadas L, Arranz-Valsero I, Lopez-Garcia A, Paulsen F, et al. Structural and functional alteration of corneal epithelial barrier under inflammatory conditions. Curr Eye Res 2012;37:971–981.
   PubMed Web of Science ®Google Scholar
• Barile FA. Validating and troubleshooting ocular in vitro toxicology tests. J Pharmacol Toxicol Methods 2010;61:136–145.
   PubMed Web of Science ®Google Scholar
• Abdelkader H, Ismail S, Hussein A, Wu Z, Al-Kassas R, Alany RG. Conjunctival and corneal tolerability assessment of ocular naltrexone niosomes and their ingredients on the hen’s egg chorioallantoic membrane and excised bovine cornea models. Int J Pharm 2012;432:1–10.
   PubMed Web of Science ®Google Scholar
• Jung KM, Lee SH, Ryu YH, Jang WH, Jung HS, Han JH, et al. A new 3D reconstituted human corneal epithelium model as an alternative method for the eye irritation test. Toxicol In Vitro 2011;25:403–410.
   PubMed Web of Science ®Google Scholar
• Cavet ME, VanDerMeid KR, Harrington KL, Tchao R, Ward KW, Zhang JZ. Effect of a novel multipurpose contact lens solution on human corneal epithelial barrier function. Contact Lens Anterior Eye 2010;33 Suppl 1:S18–S23.
   PubMed Web of Science ®Google Scholar
• Dua HS, Faraj LA, Said DG, Gray T, Lowe J. Human corneal anatomy redefined: a novel pre-Descemet’s layer (Dua’s layer). Ophthalmology 2013;120:1778–1785.
   PubMed Web of Science ®Google Scholar
• Kimura K, Teranishi S, Fukuda K, Kawamoto K, Nishida T. Delayed disruption of barrier function in cultured human corneal epithelial cells induced by tumor necrosis factor-alpha in a manner dependent on NF-kappaB. Invest Ophthalmol Vis Sci 2008;49:565–571.
   PubMed Web of Science ®Google Scholar
• Hu J, Zhang Z, Xie H, Chen L, Zhou Y, Chen W, et al. Serine protease inhibitor A3K protects rabbit corneal endothelium from barrier function disruption induced by TNF-alpha. Invest Ophthalmol Vis Sci 2013;54:5400–5407.
   PubMed Web of Science ®Google Scholar
• Goto E, Shimazaki J, Monden Y, Takano Y, Yagi Y, Shimmura S, et al. Low-concentration homogenized castor oil eye drops for noninflamed obstructive meibomian gland dysfunction. Ophthalmology 2002;109:2030–2035.
   PubMed Web of Science ®Google Scholar
• Donahue DA, Kaufman LE, Avalos J, Simion FA, Cerven DR. Survey of ocular irritation predictive capacity using Chorioallantoic Membrane Vascular Assay (CAMVA) and Bovine Corneal Opacity and Permeability (BCOP) test historical data for 319 personal care products over fourteen years. Toxicol In Vitro 2011;25:563–572.
   PubMed Web of Science ®Google Scholar
• Knagenhjelm SK, Froyland K, Ringvold A, Bjerkas E, Kjonniksen I. Toxicological evaluation of cyclosporine eyedrops. Acta Ophthalmol Scand 1999;77:200–203.
   PubMedGoogle Scholar